The therapeutic suppression of PD-L1, IDO, or CTLA-4 lowers the number of tumor-infiltrating Treg cells and improves long-term permanence, whereby a blockade of safety checkpoints can be considered an encouraging approach in glioma immunotherapy. This evidence concerns the gene IDO1 and neoplasm.